

CBMRT Transparency Webinar Series 2021

In 2021 CBMRT is running an exciting global program of virtual sessions that will focus on the latest developments in the biomedical research transparency space. Just like CBMRT's in-person, annual Biomedical Transparency Summits, participants will be updated by engaging experts who are leading transparency efforts in the policy, industry, technology, academia, publishing and funding domains (See page two for speaker profiles). Presentations will be deliberately brief (but content rich) to allow ample time for productive discussions to ensue.

Webinar One - Research Integrity: Developments across the Atlantic

Friday February 26 @ 8 - 9am ET (1 - 2pm GMT)

Prof. Ana Marušić (SoPs4RI Project Leader and Professor of Anatomy, University of Split School of Medicine) will discuss the EU's new Horizon Europe €81 billion research funding program and its strong commitment to research integrity; it is anticipated that institutions receiving Horizon funding will be required to have clear plans and procedures in place for research integrity. The Standard Operating Procedures for Research Integrity project (SOP4RI) is funded by the EC and aims to translate integrity principles into practice by stimulating transformational processes across European research organizations and funders. In the US, the NIH and the National Academies of Science are playing leading roles in recommending ways to improve research integrity. As one of the largest public funders of medical research in the world, the NIH has invested significant effort in developing policies and resources to ensure that it funds the best and most rigorous science. Michael Lauer MD (Deputy Director for Extramural Research at NIH) will provide an update on these initiatives. The panel discussion will be facilitated by Dr. Devon Crawford (Scientific Program Manager at NIH NINDS and 'Rigor Champion') and Dr. David Tovey (Co-Editor in Chief, Journal of Clinical Epidemiology).

Webinar Two - Open access: Developments across the globe

Tuesday March 16 @ 4 - 5pm ET (8 - 9pm GMT)

Across Europe, Plan S momentum continues to build with 23 major research funders endorsing the movement to make the research it funds immediately open access; Springer Nature also recently adopted the Plan S framework. The coalition has built a Journal Checker Tool to help researchers achieve Plan S compliance. In the US, the White House Office of Science and Technology Policy (OSTP) has been driving open access policy efforts, running a public consultation on "Public Access to Peer-Reviewed Scholarly Publications, Data and Code Resulting from Federally Funded Research" since early 2020. Prof. Johan Rooryck (Executive Director, coAlition S) and Dr. Ginny Barbour (Executive Director, Australasian Open Access Strategy Group) will provide updates on global developments, the varying stakeholder perspectives (including actions being taken simultaneously by funders) and the likely timeline for transition to a state of greater public access to both government and privately funded research. The panel discussion will be facilitated by Katie Steen (Policy & Advocacy Manager, Scholarly Publishing and Academic Resources Coalition) and Dr. Nick Campbell (Vice President Funder Relations, Springer Nature).

Webinar Three- Acceleration of research and implications for research transparency Friday March 26 @ 11am - 12.30pm ET (3 - 4.30pm GMT)

In this final and extended session, we will tease out the key take-aways (so far) from the pandemic for research transparency. Without doubt we are witnessing an unprecedented acceleration of the scientific discovery process, but how are we faring in terms of research quality, reporting and patient outcomes? How have journals performed, including in their peer review process? Are we seeing increased data sharing at a global level, and what's the verdict on preprints? Prof. Ida Sim (Director, UCSF Informatics and Research Innovation) will provide a unique big data, data sharing and COVID tracing perspective on these issues; Dr. John Inglis (Executive Director, Cold Spring Harbor Laboratory Press) will discuss the acceleration of preprints witnessed at medRxiv and bioRxiv, Deborah Dixon (Global Editorial Director, Oxford University Press) will provide journal/publisher insights, and Dr. Sandra Petty (CEO, CBMRT) will outline implications for publication bias. The panel discussion will be facilitated by Dr. Norbert Tavares (Program Manager, Chan Zuckerberg Initiative) and Dr. Annalisa Jenkins (Board Member, Milken Institute).



Speaker/Panellist Profiles

Michael Lauer, M.D. is the Deputy Director for Extramural Research at the National Institutes of Health (NIH). He spent 14 years at Cleveland Clinic as Professor of Medicine, Epidemiology, and Biostatistics during which time he led an internationally renowned clinical epidemiology program that applied big data from large-scale electronic health platforms to questions regarding the diagnosis and management of cardiovascular disease. From 2007 to 2015 he served as a Division Director at the National Heart, Lung, and Blood Institute (NHLBI). Michael has received numerous awards including the Arthur S. Flemming Award for Exceptional Federal Service.

<u>Prof. Ana Marušić</u> is a leader of the EU Standard Operating Procedures for Research Integrity Project (SOPs4RI) and Professor of Anatomy/Chair of the Department of Research in Biomedicine and Health at the University of Split School of Medicine, Croatia. She is Co-Editor in Chief of the *Journal of Global Health*; a Steering Group member of the EQUATOR Network; and Co-Chair of the Cochrane Scientific Committee. Prof. Marušić has more than 200 peer-reviewed articles and was heavily involved with creating the policy of mandatory registration of clinical trials in public registries which helped change the legal regulation of clinical trials worldwide.

<u>Dr. Devon Crawford</u> is a Scientific Program Manager at the NIH National Institute of Neurological Disorders and Stroke, where her focus is on improving experimental rigor and transparency within the biomedical research community as well as supporting efforts of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative. She received her Ph.D. in Neuroscience from Washington University and serves as a member of the CBMRT Scientific Advisory Committee.

<u>Dr. David Tovey</u> is Co-Editor in Chief, Journal of Clinical Epidemiology and was the first Editor in Chief of The Cochrane Library for 10 years until his retirement in 2019. He worked previously as Editorial Director for the BMJ Evidence Centre, and prior to that worked as a General Practitioner in an urban practice in South London for 15 years until 2003. David currently serves as Senior Adviser to the COVID-19 Evidence Network to support Decision-making; as Editorial Adviser to the research consortium Covid-NMA; and as Chair of the CBMRT Scientific Advisory Committee.

<u>Prof. Johan Rooryck</u> is Chief Executive of cOAlition S, an alliance of research funders working towards the implementation Plan S. He is Professor of French Linguistics at Leiden University in the Netherlands, and has over 20 years' experience as an editor, including as founder and Editor in Chief of the Fair Open Access journal *Glossa*. Johan is President of the Quality Open Access Market; founding member and President of the Fair Open Access Alliance; and Member of the Academia Europaea.

<u>Prof. Ginny Barbour</u> is Director of the <u>Australasian Open Access Strategy Group</u> and is Co-Lead, Office for Scholarly Communications, Queensland University of Technology (QUT). In 2004, she was one of the three founding editors of <u>PLOS Medicine</u>. She was <u>Chair of the Committee on Publication Ethics</u> from 2012-2017. She has been involved over the years with many Open Access, publishing, and ethics initiatives including the Declaration on Research Assessment (<u>DORA</u>) the <u>Cochrane Library Oversight Committee</u>, and as a <u>Plan S Ambassador</u>. She writes for the <u>Conversation</u>. She is on the NHMRC's <u>Research Quality Steering Committee</u>. Her ORCID profile is here http://orcid.org/0000-0002-2358-2440

<u>Katie Steen</u> is the newly appointed Policy & Advocacy Manager at SPARC (Scholarly Publishing and Academic Resources Coalition). Prior to this she served as Federal Relations Officer at the Association of American Universities Katie Steen where she was responsible for funding and policy issues related to the humanities, international education programs, and public access. Katie holds a Master of Public Affairs from the University of Missouri.

<u>Dr. Nick Campbell</u> is Vice President for Funder Relations at Springer Nature. Since joining the Nature Publishing Group in 2001 Nick has been an editor on Nature Reviews Genetics, Executive Editor of Nature, and Director of Nature Research in China. Nick's first degree, PhD and postdoctoral research were in genetics. He also has a Graduate Certificate in journalism from the University of Queensland.

<u>Ida Sim M.D. PhD.</u>, is Professor of Medicine at UCSF and co-directs Informatics and Research Innovation at UCSF's Clinical and Translational Sciences Institute. In 2005-6, she led the World Health Organization's International Clinical



Trials Registry Platform which established the first global policy on clinical trial registration. She is co-founder of two non-profit organizations: Vivli and Open mHealth and a recipient of the United States Presidential Early Career Award for Scientists and Engineers. Ida is a Fellow of the American College of Medical Informatics, a member of the American Society for Clinical Investigation, and a practicing primary care clinician.

<u>Dr. John Inglis</u> is Executive Director of Cold Spring Harbor Laboratory Press and co-founder of preprint platforms medRxiv and bioRxiv. John holds a Ph.D. in immunology from the Edinburgh University Medical School and started his publishing career with The Lancet. He founded the monthly review journal, Immunology Today (now Trends in Immunology) and moved to the US to found Cold Spring Harbor Laboratory Press, a digital publisher of 9 journals including two of the world's top genetics journals, and over 200 laboratory manuals, handbooks, and monographs used by scientists worldwide.

<u>Deborah Dixon</u> is Global Editorial Director, Science and Medical Journals at Oxford University Press and prior to this was Global Publishing Director, Health Sciences, at John Wiley & Sons. Deborah is active in in publishing, science funding and university policy development and serves on several boards including the Publishers' Licensing Service. She is a founding Trustees of Evidence Aid and a member of the CBMRT Scientific Advisory Committee.

<u>Dr. Sandra Petty</u> is an academic and clinical neurologist, medical educator, and co-founder and CEO of the Center for Biomedical Research Transparency. She currently works in epilepsy at St Vincent's Hospital, and The Alfred Hospital in Melbourne. She was previously a Senior Lecturer at The University of Melbourne Medical School focusing on curriculum development, transition to medical practice and medical cognizance. Dr. Petty is a Director of the Brain Foundation of Victoria.

<u>Dr. Norbert Tavares</u> is a Science Program Manager at the <u>Chan Zuckerberg Initiative</u>, where he primarily manages single-cell biology research programs that support the international <u>Human Cell Atlas</u> consortium. Previously, he served at the National Cancer Institute, at the National Institutes of Health as an AAAS Science & Technology Policy Fellow. Dr. Tavares is a microbiologist by training and was a Ruth Kirchstein Fellow at the University of Georgia.

<u>Dr. Annalisa Jenkins</u> is a biopharma thought leader with over 25 years of industry experience in building and financing biotech companies. Annalisa served as president and CEO of Dimension Therapeutics; was head of global research and development at Merck Serono; and held several senior positions at Bristol Myers-Squibb over 15 years. She was a medical officer in the British Royal Navy, achieving the rank of surgeon lieutenant commander. She is a committee member of the Science Board to the U.S. Food & Drug Administration; a board member at Milken Institute and CBMRT, and Chair of The Court of The London School of Hygiene and Tropical Medicine.